Notably, BTYNB, an inhibitor of IGF2BP1, has been shown to exert antiproliferative effects in IGF2BP1-expressing ovarian cancer and melanoma cells, while exhibiting no effects in IGF2BP1-negative cells [90]. This evidence concerns the gene IGF2BP1 and melanoma.